Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Delavirdine Mesylate

Known as: Delavirdine Mesylate [Chemical/Ingredient], Mesylate, Delavirdine 
A mesylate salt form of delavirdine, a synthetic, non-nucleoside reverse transcriptase inhibitor. In combination with other anti-retroviral drugs… Expand
National Institutes of Health

Related topics

Related topics

17 relations
Acquired Immunodeficiency SyndromeAlprazolamAstemizoleCisapride
Expand

Broader (3)

DelavirdineIndolesPiperazines

Narrower (2)

RescriptorU-90152

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Rifampin and rifabutin drug interactions: an update.
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes. A few examples of well-documented clinically significant… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1999
1999
efficacy and Safety of Delavirdine Mesylate With Zidovudine and Didanosine Compared With Two-drug Combinations of These Agents in Persons With Hiv Disease With Cd4 Counts of 100 to 500 cells/mm3…
To evaluate the antiretroviral activity of delavirdine mesylate, a nonnucleoside reverse transcriptase inhibitor of HIV-1, we… Expand
Is this relevant?
1998
1998
Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Administration of delavirdine, an HIV-1 reverse transcriptase inhibitor, to rats or monkeys resulted in apparent loss of hepatic… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
1997
1997
Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
OBJECTIVE To study the effect of rifampin (INN, rifampicin), a potent inducer of cytochrome P450, on the steady-state… Expand
Is this relevant?
1997
1997
Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
The oxidative metabolism of delavirdine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, is mediated in part by… Expand
Is this relevant?
1997
1997
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
1997
1997
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
OBJECTIVE The steady-state kinetics of delavirdine and desisopropyldelavirdine were evaluated in human immunodeficiency virus… Expand
  • table I
  • figure 1
  • figure 2
  • table II
  • table III
Is this relevant?
1997
1997
Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.
Delavirdine mesylate (U-90152T) is a highly specific nonnucleoside reverse transcriptase inhibitor currently under development… Expand
  • figure 2
  • figure 3
  • table 1
  • table 2
  • figure 4
Is this relevant?
Review
1996
Review
1996
Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
In summary, DLV has been well-tolerated in > 1,000 HIV-1 infected patients. Skin rash is the most prevalent medical event… Expand
Is this relevant?
1996
1996
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
Delavirdine mesylate (DLV) is a potent nonnucleoside reverse transcriptase inhibitor with activity specific for human… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE